These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 20679609)

  • 1. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
    Cortes J; Vahdat L; Blum JL; Twelves C; Campone M; Roché H; Bachelot T; Awada A; Paridaens R; Goncalves A; Shuster DE; Wanders J; Fang F; Gurnani R; Richmond E; Cole PE; Ashworth S; Allison MA
    J Clin Oncol; 2010 Sep; 28(25):3922-8. PubMed ID: 20679609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.
    Spira AI; Iannotti NO; Savin MA; Neubauer M; Gabrail NY; Yanagihara RH; Zang EA; Cole PE; Shuster D; Das A
    Clin Lung Cancer; 2012 Jan; 13(1):31-8. PubMed ID: 21862415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer.
    Aogi K; Iwata H; Masuda N; Mukai H; Yoshida M; Rai Y; Taguchi K; Sasaki Y; Takashima S
    Ann Oncol; 2012 Jun; 23(6):1441-8. PubMed ID: 21989327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance.
    Inoue K; Saito T; Okubo K; Kimizuka K; Yamada H; Sakurai T; Ishizuna K; Hata S; Kai T; Kurosumi M
    Breast Cancer Res Treat; 2016 Jun; 157(2):295-305. PubMed ID: 27125669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
    McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
    Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.
    Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA
    Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial.
    Gitlitz BJ; Tsao-Wei DD; Groshen S; Davies A; Koczywas M; Belani CP; Argiris A; Ramalingam S; Vokes EE; Edelman M; Hoffman P; Ballas MS; Liu SV; Gandara DR
    J Thorac Oncol; 2012 Mar; 7(3):574-8. PubMed ID: 22198425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
    Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
    BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
    Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
    Paillard MJ; Curtit E; Dobi E; Mansi L; Bazan F; Villanueva C; Chaigneau L; Montcuquet P; Meneveau N; Thiery-Vuillemin A; Nerich V; Pivot X
    Bull Cancer; 2015 Sep; 102(9):737-48. PubMed ID: 26022285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.
    Yardley DA; Reeves J; Dees EC; Osborne C; Paul D; Ademuyiwa F; Soliman H; Guthrie T; Andersen J; Krekow L; Choksi J; Daniel B; Danso M; Favret A; Oommen S; Brufsky A; Bromund JL; Lin Y; Ibrahim AB; Richards PD
    Clin Breast Cancer; 2016 Dec; 16(6):471-479.e1. PubMed ID: 27569274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.
    de Bono JS; Molife LR; Sonpavde G; Maroto JP; Calvo E; Cartwright TH; Loesch DM; Feit K; Das A; Zang EA; Wanders J; Agoulnik S; Petrylak DP
    Ann Oncol; 2012 May; 23(5):1241-1249. PubMed ID: 21903605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital.
    Poletti P; Ghilardi V; Livraghi L; Milesi L; Rota Caremoli E; Tondini C
    Future Oncol; 2014 Feb; 10(2):233-9. PubMed ID: 24490609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin.
    Perry CM
    Drugs; 2011 Jul; 71(10):1321-31. PubMed ID: 21770478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
    Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
    Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.